
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is a leading player in the cardiovascular medical devices and technology market, with a strong portfolio of products targeting aortic disease and a presence in key markets such as North America, EMEA, and APAC. The company has a positive growth outlook, driven by new product launches and international expansion, and is expected to see sustained revenue growth of 8-12% in the coming years. While faced with competition and regulatory risks, Artivion's strong product mix and continued investment in R&D and expansion efforts can support solid margin improvement.
Bears say
Artivion is facing a slight setback and a slowdown in revenues due to barriersto adoption and upfront costs associated with its AMDS graft product. However, the company is taking steps to improve these issues and has a robust pipeline in place for future growth opportunities. Additionally, the recent acquisition of Endospan and its PMA approved aortic stent product indicates potential for long-term growth. While a slight adjustment in revenue and earnings estimates is warranted, the stock still remains an attractive investment with solid fundamentals and strong potential for margin and EBITDA growth.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares